Ekf Diagnostics Holdings Plc · LSE:EKF
Ekf Diagnostics — FY2021 Earnings Presentation
24 slides from Ekf Diagnostics's earnings presentation, March 2022
Slide 1: FY21 Results Presentation
EKF Diagnostics Holdings plc FY21 RESULTS PRESENTATION March 2022
Slide 2: Leadership
Mike Salter Leadership CEO • Joined EKF in October 2017. Chief Executive Officer of EKF Diagnostics since 1st October 2021 • As EKF US President Mike was responsible for overseeing the growth of EKF’s business in the Americas, and introduced the implementation of contract manufacturing COVID-19 test
Slide 3: Building a leading global diagnostics business
Building a leading global diagnostics business LAB SERVICES POINT OF CARE CENTRAL LABORATORY LIFE SCIENCES (ADL HEALTH) CLIA certified facility POCT portfolio: Clinical chemistry Enzyme fermentation • Hemoglobin and reagents including: • EKF enzymes hematocrit • β-Hydroxybutyrate • Third party • HbA
Slide 4: Investing, innovating and integrating for growth
Investing, innovating and integrating for growth 2021 Diversification into Laboratory Testing services Acquisition of ADL and integration into wider EKF business Investment in high-potential Life Sciences sector Investing in further capacity and capabilities for significant growth Development of new
Slide 5: FY21 Financial Review
FY21 Financial Review ar Diagnostics
Slide 6: FY21 Financial highlights
FY21 Financial highlights 81.8 Revenue Gross Profit Adj-EBITDA 65.3 up 25% up 5% up 4% £81.8m 2021 £39.4m 2021 £26.5m 2021 44.9 41.6 42.5 £M £65.3m 2020 £37.4m 2020 £25.5m 2020 25.5 26.5 PBT Basic Net Cash* £21.4m Earnings per 10.7 12.0 £19.6m 9.3 share 3.47p 2021 £21.4m 2020 2017 2018 2019 2020 202
Slide 7: Operational highlights
Revenue Development Operational highlights 90 80 Point of Care, Central Laboratory and Life Sciences revenues increased to £42.1m from £37.1m (↑ 14%): 70 • Point of Care revenues up 18% • Central Laboratory revenues up 7% 60 • Life Science revenues up 3% £'m Contract Manufacturing and Testing revenu
Slide 8: Strong cash generation
Strong cash generation CASH CONVERSION** 106% (2020: 86%) ** excluding share-based payments £20.6m cash generated through operating activities, excluding share-based payments • £6.7m working capital increase to support 2021 revenue growth £5.7m capital expenditure to fuel growth • £4.3m excluding IF
Slide 9: Business Segments Analysis
Business Segments Analysis ar Diagnostics
Slide 10: Global revenue breakdown and distribution network
Global revenue breakdown APAC Strong return of HbA1c business in the Philippines and significant tender wins in India for DiaSpect Tm analysers and cuvettes. EMEA Continued demand in UK and Ireland for sample collection tubes and kits from multiple public health and private sector customers. Additio
Slide 11: Point of Care FY 2021 Diabetes range
Point of Care FY 2021 Diabetes range Diabetes Biosen C-Line Quo-Lab A1c Revenues up £1,190k (↑ 13%) as COVID restrictions were relaxed allowing Quo-Test A1c more testing to be undertaken Biosen up £477k (↑ 10%) Quo-Lab up £384k (↑ 15%) Quo-Test up £329k (↑ 18%) 2021 £k 2020 £k +/- £k +/- % Diabetes
Slide 12: Point of Care FY 2021 Hematology range
Point of Care FY 2021 Hematology Hematology range DiaSpect Tm Revenues up £2,105k (↑ 19%). Anaemia screening programmes and blood Hemo Control banking initiatives restarted post-pandemic HemoPoint H2 DiaSpect Tm up £959k (↑ 23%) HemataStat II • Strong performances from McKesson and Fresenius OEM agr
Slide 13: Point of Care FY 2021 Other PoC devices
Point of Care FY 2021 Other PoC Inc. Lactate, Pregnancy tests devices Creamatocrit Revenues up £634k (↑ 27%). Lactate Scout Lactate Scout up £310k (↑ 27%) Pregnancy • Return to competitive sport and Olympic year Uri-Trak Pregnancy testing up £298k (↑ 26%) • More hospital procedures undertaken • Retu
Slide 14: Central Laboratory FY 2021
Central Laboratory FY 2021 Clinical Chemistry and lab analysers Revenues up £903k (↑ 7%) β-HB up £791k (↑ 8%) Central Lab Clinical chemistry Clinical Chemistry sales up despite supply chain Small lab analysers challenges with raw materials and consumables Centrifuges Increased demand for Glycated Al
Slide 15: Life Sciences FY 2021
Life Sciences FY 2021 Life Sciences Enzyme fermentation Enzyme manufacturing Bulk fermentation Custom products Revenues up £60k (↑ 3%) Investment of $10m into new facilities in South Bend, Indiana Continued investment into Elkhart facility Strong pipeline of opportunities from new customers to utili
Slide 16: Contract Manufacturing FY 2021
Contract Manufacturing FY 2021 Bulk formulation and kitting services Revenues up £9,994k to £36,308k (38%) Driven by demand for molecular transport media Contract tubes and kits from public sector and private Manufacturing sector customers in Europe Bulk molecular Demand for PBS increased in USA thr
Slide 17: Lab Services FY 2021
Lab Services FY 2021 ADL Health Lab Services COVID PCR test NIPT test Primarily focused on COVID-19 testing services for private business and Calprotectin test individuals Continued demand expected in 2022, particularly as a supplier of COVID-19 testing services for large events On-boarding new test
Slide 18: Growth Strategy
Growth Strategy ar Diagnostics
Slide 19: Growth plan 2022 – 2024
Growth plan 2022 – 2024 Continuing innovation in products and services innovation in Point- of- Care, Central Laboratory and Life Sciences leveraging existing routes to market and relationships Investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufac
Slide 20: Lab Services - ADL Health: CLIA certified lab
Lab Services - ADL Health: CLIA certified lab Acquired October 2021 29 staff based in San Antonio, Texas COVID testing for travel, sport, entertainment and industry Full traceability and tracking of sample to result Online customer support Introduction of NIPT testing in March 2022 in collaboration
Slide 21: Life Sciences and Contract Manufacturing
Life Sciences Based in Elkhart, Indiana. Development, tech transfer and 1600 litre fermentation capabilities. Certified ISO 13485: 2016 facility. FDA registered Continued investment in site upgrade and new fermenting technology Second plant opened in South Bend, Indiana to provide increased capacity
Slide 22: Preferred partnership with Mount Sinai Innovation Partners
Preferred partnership with Mount Sinai Innovation Partners Preferred partnership agreement with Mount Sinai Innovation Partners (MSIP), NYC (Sept. 2019) • Agreement provides EKF with advanced access to innovative commercial opportunities arising from Mount Sinai Health System (MSHS) owned technologi
Slide 23: 2022 Outlook
2022 Outlook Revenue Investment Innovation Q1 2022 revenues expected to Installation of fermentation Pipeline of product and services be in-line with Q1 2021 equipment in Elkhart and South development: Bend to be completed by end of • Launch of EKF Link connectivity FY 2022 revenue targets: 2022 sof
Slide 24: Disclaimer
Disclaimer The information contained in these slides and the accompanying oral presentation (together, the “Presentation”) has been prepared by EKF Diagnostics Holdings plc (the “Company”). The Presentation is subject to updating, completion, revision and amendment without notice and as such it may
EKF Diagnostics Holdings — FY2021 Earnings Presentation on 6ix